Onconova Therapeutics, Inc. (NASDAQ:ONTX) Short Interest Update

Onconova Therapeutics, Inc. (NASDAQ:ONTXGet Free Report) saw a large decline in short interest in the month of January. As of January 31st, there was short interest totalling 54,500 shares, a decline of 44.8% from the January 15th total of 98,700 shares. Based on an average daily volume of 232,100 shares, the days-to-cover ratio is presently 0.2 days.

Onconova Therapeutics Price Performance

NASDAQ ONTX traded down $0.01 during trading on Monday, reaching $0.68. The company’s stock had a trading volume of 71,305 shares, compared to its average volume of 48,930. The firm has a fifty day moving average of $0.71 and a 200 day moving average of $0.74. The stock has a market capitalization of $14.32 million, a PE ratio of -0.70 and a beta of 1.33. Onconova Therapeutics has a one year low of $0.55 and a one year high of $1.45.

Onconova Therapeutics (NASDAQ:ONTXGet Free Report) last released its earnings results on Tuesday, November 14th. The biopharmaceutical company reported ($0.23) EPS for the quarter, beating analysts’ consensus estimates of ($0.26) by $0.03. Onconova Therapeutics had a negative return on equity of 95.43% and a negative net margin of 8,930.97%. The business had revenue of $0.06 million for the quarter, compared to analysts’ expectations of $0.06 million. Research analysts expect that Onconova Therapeutics will post -0.94 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

Separately, StockNews.com initiated coverage on shares of Onconova Therapeutics in a report on Monday. They set a “sell” rating on the stock.

Check Out Our Latest Stock Report on Onconova Therapeutics

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently bought and sold shares of the business. Renaissance Technologies LLC grew its stake in shares of Onconova Therapeutics by 140.8% during the first quarter. Renaissance Technologies LLC now owns 321,743 shares of the biopharmaceutical company’s stock valued at $592,000 after buying an additional 188,116 shares during the last quarter. Vanguard Group Inc. grew its stake in shares of Onconova Therapeutics by 21.7% during the third quarter. Vanguard Group Inc. now owns 622,958 shares of the biopharmaceutical company’s stock valued at $549,000 after buying an additional 110,965 shares during the last quarter. Beacon Pointe Advisors LLC grew its holdings in shares of Onconova Therapeutics by 147.0% in the first quarter. Beacon Pointe Advisors LLC now owns 46,027 shares of the biopharmaceutical company’s stock worth $85,000 after purchasing an additional 27,396 shares during the last quarter. Finally, Millennium Management LLC grew its holdings in shares of Onconova Therapeutics by 154.6% in the second quarter. Millennium Management LLC now owns 61,390 shares of the biopharmaceutical company’s stock worth $81,000 after purchasing an additional 37,275 shares during the last quarter. 8.85% of the stock is currently owned by institutional investors.

About Onconova Therapeutics

(Get Free Report)

Onconova Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on discovering and developing novel products to treat cancer in the United States. It has two clinical-stage programs, including narazaciclib, a multi-targeted kinase inhibitor that is in Phase I study for solid tumors, as well as hematological malignancies as a single agent or in combination with other anti-cancer therapies; and oral rigosertib alone or in combination with PD-1 inhibitor, which is in Phase I/IIa study for the treatment of progressive K-Ras mutated non-small cell lung cancer.

Read More

Receive News & Ratings for Onconova Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Onconova Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.